Denali Therapeutics

Path: /organizations/denali-therapeutics Type: Biotechnology Company Headquarters: South San Francisco, California, USA Founded: 2013 Stock: NASDAQ: DNLI Market Cap: ~$2.5 billion (2025) Key Investors: Flagship Pioneering, venBio, T. Rowe Price

Overview

Path: /organizations/denali-therapeutics Type: Biotechnology Company Headquarters: South San Francisco, California, USA Founded: 2013 Stock: NASDAQ: DNLI Market Cap: ~$2.5 billion (2025) Key Investors: Flagship Pioneering, venBio, T. Rowe Price

Overview

Denali Therapeutics is a US biotechnology company headquartered in South San Francisco, California, focused on developing therapies for neurodegenerative diseases. Founded in 2013 as a spinout from Genentech, Denali has pioneered a unique approach to CNS drug delivery using its proprietary [TransportVehicle™ (TV) platform](/mechanisms/transport-vehicle-cns-delivery), which enables therapeutic molecules to cross the blood-brain barrier by hijacking transferrin receptor-mediated transcytosis["@transport_vehicle"].

The company's name "Denali" references the highest mountain in North America, reflecting its ambition to tackle the highest peaks of neurological disease. Denali has positioned itself at the intersection of genetic targets (LRRK2, GBA, TREM2, SNCA) and engineered delivery platforms, forming partnerships with major pharma companies including Biogen and Takeda.

Pipeline Overview

Denali's pipeline spans five therapeutic areas: lysosomal storage disorders, Parkinson's disease, Alzheimer's disease, ALS/frontotemporal dementia, and inflammatory diseases. The company uses two main delivery platforms: ETS (Engineered Transport System) for enzyme replacement therapies and OTV (Organism-Targeted Vehicle) for targeted CNS delivery of various cargo types.

Clinical Development Programs

| Program | Target | Indication | Phase | Notes |
|---------|--------|-----------|-------|-------|
| Tividenofusp alfa (ETV:IDS) | IDS enzyme | MPS II (Hunter syndrome) | Phase 2/3 | Lead lysosomal program |
| BIIB122 / DNL151 | LRRK2 | Parkinson's disease | Phase 2b | Partnered with Biogen |
| DNL126 (ETV:SGSH) | SGSH enzyme | MPS IIIA (Sanfilippo A) | Phase 1/2 | NCT06181136 |
| TAK-594 / DNL593 (PTV:PGRN) | Progranulin | FTD-GRN | Phase 1/2 | NCT05262023; partnered with Takeda |
| DNL952 (ETV:GAA) | GAA enzyme | Pompe disease | Phase 1 | |
| DNL628 (OTV:MAPT) | MAPT/tau | Alzheimer's disease | Phase 1 | |
| Eclitasertib | RIPK1 | Ulcerative colitis | Phase 2 | Peripheral RIPK1 inhibitor |

Preclinical and IND-Enabling Programs

| Program | Target | Indication |
|---------|--------|-----------|
| DNL921 (ATV:Abeta) | Amyloid-beta | Alzheimer's disease |
| DNL111 (ETV:GCase) | GCase | Parkinson's / Gaucher diseases |
| DNL622 (ETV:IDUA) | IDUA enzyme | MPS I (Hurler syndrome) |
| DNL422 (OTV:SNCA) | Alpha-synuclein | Parkinson's disease |

Key Programs in Detail

LRRK2 Inhibitor — BIIB122 / DNL151

The LRRK2 inhibitor program represents Denali's most advanced neurodegeneration pipeline asset, partnered with Biogen for global development and commercialization.

Background: [LRRK2](/genes/lrrk2) (Leucine-Rich Repeat Kinase 2) mutations are among the most common genetic causes of Parkinson's disease, with the G2019S mutation accounting for approximately 1-2% of sporadic PD and 4-5% of familial PD[@lrrk2_tau]. LRRK2 is a large multi-domain protein with kinase activity that phosphorylates Rab GTPases (particularly Rab8a, Rab10, Rab12, Rab35), regulating lysosomal function, cilia function, and autophagy[@parkinson2024].

Mechanism: Pathogenic LRRK2 mutations (G2019S, R1441C/G/H, Y1699C) increase kinase activity, leading to:

BIIB122 (DNL151) is an orally bioavailable, brain-penetrant small molecule LRRK2 kinase inhibitor:

• Selectively inhibits LRRK2 kinase activity
• Reduces phosphorylated Rab10 (pRab10) as a pharmacodynamic biomarker
• Demonstrated safety and tolerability in Phase 1 studies[@bii122_phase1]
• Phase 2b trial in early-stage Parkinson's disease patients (with and without LRRK2 mutations)

• Phase 1 (DNL151): Safety, tolerability, and pharmacokinetics in healthy volunteers — completed
• Phase 2b: LRRK2 inhibitor vs. placebo in early-stage Parkinson's disease — currently enrolling

• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) (tauopathy with overlapping neuropathology)
• [Alzheimer's Disease](/diseases/alzheimers-disease) (inflammation-driven neurodegeneration)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) (C9orf72-linked)

TREM2 Programs

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a microglial surface receptor critical for amyloid-beta clearance and neuroinflammatory regulation. Denali is developing TREM2-targeted programs for [Alzheimer's disease](/diseases/alzheimers-disease)[@trem2_microglia].

Mechanism of TREM2 in Alzheimer's disease:

DNL919 (TREM2 agonist): Antibody-based TREM2 modulator for Alzheimer's disease — in preclinical/early clinical development

See [TREM2 Signaling](/mechanisms/trem2-signaling) for detailed mechanisms.

GCase Programs — DNL111

[Glucocerebrosidase](/genes/gba) (GCase) is a lysosomal enzyme that metabolizes glucosylceramide. GBA mutations are the most common genetic risk factor for [Parkinson's disease](/diseases/parkinsons-disease), with heterozygous GBA mutation carriers having 5-20x increased PD risk. Denali is developing gene therapy and small molecule approaches to restore GCase activity.

DNL111 (ETV:GCase): An engineered lysosomal enzyme replacement therapy delivering functional GCase to the brain via the TransportVehicle platform[@gcase_terr]:

• Preclinical data show increased GCase activity in brain and peripheral tissues
• Being developed for both Parkinson's disease (GBA-linked) and Gaucher disease
• Crosses the blood-brain barrier more efficiently than wild-type GCase

Alpha-Synuclein Program — DNL422

DNL422 (OTV:SNCA): An organism-targeted vehicle carrying RNA interference or antisense oligonucleotides targeting [SNCA](/genes/snca) (the alpha-synuclein gene). This approach aims to reduce alpha-synuclein protein production at the source, addressing the上游 of pathological aggregation.

Rationale:

• Alpha-synuclein is the primary component of Lewy bodies in [Parkinson's disease](/diseases/parkinsons-disease) and Dementia with Lewy Bodies
• Reducing SNCA expression could prevent or slow aggregation
• OTV platform enables CNS delivery of oligonucleotides that would otherwise not cross the BBB

RIPK1 Programs

Eclitasertib (DNL300): A peripheral RIPK1 (Receptor-Interacting Serine/Threonine Kinase 1) inhibitor developed for inflammatory diseases[@ripk1_denali]. While primarily targeting ulcerative colitis, RIPK1 inhibition has relevance for neurodegeneration given its role in necroptosis and neuroinflammation.

TransportVehicle™ Platform

Denali's proprietary TransportVehicle (TV) platform is a key differentiator enabling CNS delivery of diverse therapeutic modalities[@transport_vehicle]:

Mechanism:

Platform configurations:

• ETS (Engineered Transport System): For enzyme replacement therapies (e.g., ETV:IDS for MPS II)
• OTV (Organism-Targeted Vehicle): For oligonucleotides, peptides, and other large molecules (e.g., OTV:MAPT, OTV:SNCA)
• ATV (Antibody-Targeted Vehicle): For antibody therapeutics (e.g., ATV:Abeta for Alzheimer's)

• GCase delivery (DNL111) for GBA-linked Parkinson's and Gaucher disease
• Tau reduction (DNL628, DNL921) for Alzheimer's disease
• Alpha-synuclein reduction (DNL422) for Parkinson's disease

Partnerships

| Partner | Programs | Details |
|---------|---------|---------|
| Biogen | BIIB122/DNL151 (LRRK2) | Global co-development and commercialization; Biogen leads late-stage development |
| Takeda | DNL593 (PTV:PGRN, FTD-GRN) | Collaboration for progranulin (GRN) program; Takeda leads TAK-594 |
| Genentech | Original founder organization | Founding science and platform development |
| Sirana | RNA-based therapies | Acquired for additional CNS delivery capabilities |

Financial Information

• Market Cap: ~$2.5 billion (2025)
• Cash Position: >$500M
• Revenue: Minimal (pre-commercial, research-stage)
• R&D Focus: ~85% of operating expenses directed to R&D
• Key Investors: Flagship Pioneering, venBio, T. Rowe Price, GV (Google Ventures)

Leadership

• CEO: Carole Ho, MD — formerly at Genentech and Roche
• CSO: Steve H. K. Finkbeiner, MD, PhD — pioneer in ALS and neurodegeneration research
• CFO: Ingrid M. W. Zhang
• CMO: Mark Forman, MD, PhD

Relevance to PSP and Related Disorders

Denali's programs have broader relevance for tauopathies and atypical parkinsonism:

Progressive Supranuclear Palsy (PSP):

• LRRK2 inhibitors may benefit PSP patients with LRRK2 variants or neuroinflammatory components
• TREM2 biology is relevant to microglial dysfunction in PSP
• The TransportVehicle platform could be adapted for PSP therapeutics

• Similar neuroinflammatory pathways to PSP
• LRRK2 and TREM2 mechanisms may overlap with CBS pathology

• Direct programs: DNL628 (tau), DNL921 (Abeta), DNL919 (TREM2)
• LRRK2 inhibitors may address neuroinflammation component of AD

See Also

• [LRRK2 Pathway in Parkinson's](/mechanisms/lrrk2-pathway-parkinsons)
• [GBA Pathway in Parkinson's](/hypotheses/gba-pathway)
• [TREM2 Signaling](/mechanisms/trem2-signaling)
• [Transport Vehicle CNS Delivery](/mechanisms/transport-vehicle-cns-delivery)
• [Parkinson's Disease Treatment Pipeline](/companies/pd-pipeline)
• [Biogen](/organizations/biogen)
• [Alzheimer's Disease](/diseases/alzheimers-disease)

References